Purpose. Implementation of a standardized daptomycin dosing protocol in a community teaching hospital to determine potential cost savings, effectiveness, and safety is presented.
Methods. A retrospective review of randomly selected patients receiving daptomycin therapy from October 2013 to January 2014 was performed to establish a preimplementation patient control group. A specific time for preparing daptomycin in the i.v. room was used based on a standardized administration time of 4 p.m. Reconstituted doses were stored for up to 48 hours in the refrigerator in plastic syringes. All daptomycin doses were given by rapid i.v. administration. For all patients who received daptomycin, the protocol specified that a baseline creatine phosphokinase level be evaluated within 24 hours of the start date and on day 3, day 7, and weekly thereafter until daptomycin therapy was completed or discontinued.
Results. The most frequent indications for daptomycin use preimplementation and postimplementation were related to catheter use or persistent bacteremia and skin and soft tissue infections. Through the implementation of the standardized dosing nomogram and optimization of i.v. room workflow, the amount of waste decreased by 21,500 mg and generated a savings of $13,845 over the course of the four-month study period, which can be extrapolated to $41,535 annually. The infection cure rate at completion of therapy was 56.7% in the preimplementation population compared with 70.0% in the postimplementation population. Daptomycin was well tolerated at the standardized doses used in the study.
H ealthcare-associated infections continue to be a growing concern in hospitals. Eight pathogens account for approximately 80% of reported infections, with Staphylococcus aureus and Enterococcus being the two most common organisms isolated.
1 A major concern arises because these organisms become resistant to the antibiotics most commonly used to treat them. Drug-resistant organisms such as methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) are often associated with increased rates of morbidity and mortality. 2, 3 Daptomycin is a bactericidal cyclic lipopeptide used for broadspectrum coverage of gram-positive bacteria, including drug-resistant pathogens such as MRSA and VRE. Daptomycin is used in complicated skin and soft tissue infections and for S. aureus bacteremia secondary to i.v. lines or right-sided endocarditis. 4 It has also been studied for the treatment of osteomyelitis, prosthetic joint infections, and septic arthritis, although these are off-label indications. 4, 5 Daptomycin is tolerated at mean doses of 8 mg/kg/day for a median duration of 25 days and at doses up to 12 mg/kg/day for 14 days without serious adverse events. 6, 7 Optimal dosing of daptomycin is important for both safety and effectiveness. Determining the optimal weight for daptomycin dosing has raised much debate, especially in obese patients. The package insert for daptomycin recommends using actual body or total body weight (TBW) to determine dosage; however, other studies have challenged this recommendation. 4 One study found that when using TBW in patients considered obese, and morbidly obese, both the maximum serum concentration (C max ) and the area under the concentration-time curve (AUC) were 25-30% higher in the obese population compared to the nonobese control group. 8 A similar study concluded that using TBW in obese patients (resulting in higher daily doses of daptomycin) also resulted in higher C max and AUC values in obese patients compared to nonobese patients. 9 In contrast, another study concluded that dosing daptomycin based on fat free weight, ideal body weight, and lean body weight resulted in median AUC 0-Inf values that were nearly 29% lower in obese patients and suggested dosing daptomycin based on adjusted body weight (ABW). 10, 11 Adverse events that may occur if patients are exposed to high-dose daptomycin include an elevation in creatine phosphokinase (CPK) levels. 7 This was observed in patients taking daptomycin, but studies have shown a resolution to normal CPK levels within one week of discontinuation and no long-term harmful effects. 7, 12, 13 Postmarketing surveillance has revealed a concern for eosinophilic pneumonia with daptomycin, and several case reports have been documented. 14 
Background
Traditionally at McLeod Regional Medical Center, pharmacists use a patient's TBW and round daptomycin doses to the nearest 10 mg, with a maximum dose of 1,000 mg. Based on the current dosing and preparation process, a four-month retrospective analysis revealed 30,000 mg of daptomycin were wasted, resulting in a loss of more than $20,000 a quarter. The main cause of waste was attributed to patient-specific doses that could not be reallocated to another patient if therapy was discontinued following preparation and prior to administration of the drug. Daptomycin takes roughly 45 minutes to reconstitute. 4 To prevent unnecessary reconstitution of the drug, i.v. pharmacy room workflow could be optimized by creating a batching process and standardized administration time for any patient receiving daptomycin therapy.
Based on the published literature and this analysis of daptomycin use, pharmacist intervention can potentially reduce medication waste and product cost for the health system. 15, 16 However, there are currently no data to validate if using recommended standardized (350, 500, 750, and 1000 mg) doses can produce the same clinical outcomes of effectiveness and safety as nonstandardized doses. 15 In this article, we report the design, implementation, and cost savings of a standardized daptomycin dosing nomogram in a community teaching hospital. The primary objective of the study was to determine cost savings based on a standardized dosing nomogram. The secondary objective was to ensure the effectiveness and safety of the protocol.
Methods
A retrospective review of randomly selected patients receiving daptomycin therapy from October 2013 to January 2014 was performed to establish a preimplementation patient control group. The postimplementation group included patients initiated according to the standardized daptomycin dosing nomogram who were at least 18 years of age, not pregnant, and receiving daptomycin therapy for a minimum of 72 hours from October 2014 to January 2015. This study was approved by the institutional review board.
The nomogram recommends specific doses based on the physician's selection of 6, 8, or 10 mg/kg for various indications, as shown in Table 1 . 4, 5 Nomogram doses were determined using TBW, per the package insert recommendation. 4 If patients weighed more than 120 kg, ABW was used to calculate doses (capping at 1000 mg per dose). ABW was used per recommendations of studies that concluded using ABW resulted in similar serum concentrations of daptomycin in obese patients when compared with nonobese patients. [8] [9] [10] [11] Prescribers selected a weight-based dose of daptomycin, and the ap-S108 AM J HEALTH-SYST PHARM | VOLUME 73 | SUPPLEMENT 4 | SEPTEMBER 1, 2016 propriate total dose was calculated by the pharmacist according to the TBW or ABW of the patient at order verification. The frequency was adjusted according to the patient's renal function, as calculated by the Cockcroft-Gault equation and scheduled per the guidelines in Table 2. To prepare for the protocol's implementation, educational sessions on daptomycin and the protocol were conducted for all pharmacist by pharmacy residents.
A specific time for preparing daptomycin in the i.v. room was used based on a standardized administration time of 4 p.m. Reconstituted doses were stored for up to 48 hours in the refrigerator in plastic syringes. All daptomycin doses were given by rapid i.v. administration. After one dose of daptomycin was ordered by a provider, a pharmacist performed a full review of the patient and entered appropriate subsequent doses into the medical record. A real-time automated report of active daptomycin orders was reviewed daily, and pharmacists made interventions as necessary. Patients were monitored until completion of therapy, discontinuation of therapy, or patient discharge. Patients were also followed for 30 days following discharge to document readmission.
For all patients who received daptomycin, the protocol specified that a baseline CPK level be evaluated within 24 hours of the start date and on day 3, day 7, and weekly thereafter until daptomycin therapy was completed or discontinued. 17 If the CPK level increased to 1.5 times the upper normal limit or higher, the physician was notified and asked to address if daptomycin therapy was to be continued or changed.
The primary endpoint was cost savings based on the reduction of wasted drug and improved pharmacy workflow. The secondary endpoints included effectiveness based on the rate of infection cure and safety. Infection cure was defined as normalization of white blood cells (WBCs), 4,800-10,800 cells/mm 3 , within 72 hours of the start date; normalization of temperature, 96.8-100.4 °F, within 72 hours of the start date; negative blood cultures within 7 days of the start date; and no readmission for the same infective organism within 30 days of the stop date. Safety was determined by the occurrence of adverse events, including thrombophlebitis, injection site reaction, or anaphylaxis following administration. Patients' CPK levels were monitored and assessed for signs and symptoms of rhabdomyolysis.
Results
Daptomycin was ordered in the preimplementation and postimplementation study period for 38 and 42 patients, respectively. Thirty randomly selected patients were included in the analysis for the preimplementation phase. For the postimplementation phase, 30 patients met inclusion criteria. Of the other 12 patients, 9 were excluded because the duration tion, or anaphylaxis were seen. CPK levels were monitored throughout therapy. Mean CPK levels remained similar to baseline over the course of therapy (Table 6 ). One case of rhabdomyolysis occurred in the preimplementation group. There were no cases of rhabdomyolysis reported in the postimplementation group, but one case of eosinophilic pneumonia was suspected.
Discussion
This study found the implementation of a standardized daptomycin dosing nomogram and improvements to pharmacy workflow reduced waste, thereby reducing the cost burden of this antibiotic. The standardized dosing protocol did not impair the effectiveness of therapy in our adult hospitalized patients and was well tolerated, with no notable adverse events or changes in CPK levels.
This protocol did not include a restriction of daptomycin prescribing to only infectious diseases specialists. Education on appropriate daptomycin dosing, frequency of use, and safety monitoring was given to pharmacists. This allowed of therapy was less than 72 hours and 3 were excluded because they were not initiated on the established daptomycin protocol. Baseline characteristics were similar between the preimplementation and postimplementation groups, as demonstrated in Table 3 . The most frequent indications for daptomycin use preimplementation and postimplementation were related to catheter use or persistent bacteremia and skin and soft tissue infections, as displayed in Table 4 . MRSA, the most common pathogen identified, accounted for 33% of infections in the preimplementation group and 50% of infections in the postimplementation group.
Through the implementation of the standardized dosing nomogram and optimization of i.v. room workflow, the amount of waste decreased by 21,500 mg. This reduction was due to the use of a batching process, which allowed doses to be made at one standard time every day and reduced the total number of vials used. The use of standardized doses allowed for the reallocation of prepared doses in patients who had discontinued daptomycin therapy, which historically was not an option. This reduction in waste generated a savings of $13,845 over the course of the four-month study period, which can be extrapolated to $41,535 annually.
The infection cure rate at completion of therapy was 56.7% in the preimplementation population compared with 70.0% in the postimplementation population (Table 5) . WBC counts normalized within 72 hours from the start of daptomycin therapy in 73.3% and 80.0% of the preimplementation and postimplementation populations, respectively. All patients in both the preimplementation and postimplementation groups had temperature normalization within 72 hours after initiating daptomycin therapy. Repeat negative cultures were confirmed in 86.7% of preimplementation patients and 90.0% of postimplementation patients. Rates of readmission with the same infective organism within 30 days were 20.0% and 6.7% in the preimplementation and postimplementation populations, respectively.
Daptomycin was well tolerated at the standardized doses used in the study. No reports of adverse events of thrombophlebitis, injection site reac- for improved dosing of daptomycin and decreased waste without restriction of the antimicrobial agent. After implementation, we identified the potential for increased cost savings by specifying the appropriate indication based on weight-based dosing. These indications were added to the standardized dosing nomogram, as shown in Table 1 . Pharmacy i.v. room workflow was improved by creating a standardized time to prepare daptomycin based on a standardized administration time. This allowed pharmacists time to reassess if daptomycin therapy was warranted and make daily interventions as necessary. Also, by implementing standardized doses, we were able to eliminate patientspecific doses, which allowed for prepared doses to be used for any patient.
In our study, 30% of patients did not obtain an infection cure. Failure to meet the definition of infection cure was due to normalization of WBCs after 72 hours or change in therapy before normalization of WBCs. Three patients did not respond to daptomycin therapy because of an unidentified source of infection with repeat positive blood cultures. The rate of safety monitoring increased, with routine CPK levels being ordered for all patients initiated on daptomycin because they were ordered by pharmacists per the approved protocol.
Conclusion
Implementation of a standardized dosing nomogram reduced the amount of daptomycin wasted and resulted in cost savings. The standardized dosing nomogram did not impair the rate of clinical effectiveness or cause adverse events.
